Foley Hoag Represents Zosano Pharma in IPO on Nasdaq
January 27, 2015
Foley Hoag LLP announced that it recently represented Fremont, CA.-based Zosano Pharma (Nasdaq: ZSAN) on the successful completion of its initial public offering of 4,500,000 shares of its common stock at a price of $11.00 per share. Ladenburg Thalmann and Roth Capital Partners served as joint book-running managers for the IPO and Zosano granted them a 30-day option to purchase up to 675,000 additional shares of its common stock.
Zosano is a clinical stage specialty pharmaceutical company that has developed a proprietary transdermal microneedle patch system to deliver its proprietary formulations of existing drugs through the skin for the treatment of a variety of indications.
Foley Hoag attorneys Robert Sweet, Jeff Quillen, Joel Needleman and James Schneider advised Zosano in connection with the IPO.
About Foley Hoag LLP
Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse backgrounds, perspectives and experiences of our lawyers and staff contribute to the exceptional service we deliver to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.